BSEM BioStem Technologies Inc

BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference

BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference

The presentation will be webcast at 1:30 PM ET on April 10, 2025

POMPANO BEACH, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that its Chief Executive Officer, Jason Matuszewski, will present at the 24th Annual Needham Virtual Healthcare Conference at 1:30 PM ET on Thursday, April 10, 2025. Management will also be hosting investor meetings during the conference.

BioStem Technologies Presentation Access:

  • Presenter: Jason Matuszewski, Chief Executive Officer
  • Date: Thursday, April 10, 2025
  • Time: 1:30 PM ET
  • Webcast Link & Archive:
  • 1-on-1 Meeting Request:

Join BioStem’s Distribution List & Social Media:

To follow the latest developments at BioStem, sign-up to the Company’s email distribution list , and follow us on and .

About BioStem Technologies, Inc. (OTC: BSEM):

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain®processing method. BioREtain®has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.

For more information visit and follow us on and .

BioStem Technologies, Inc.

Phone: 954-380-8342

Website: E-Mail: X: Facebook:

Investor Relations

Adam Holdsworth

917-497-9287



EN
27/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioStem Technologies Inc

 PRESS RELEASE

BioStem Technologies Announces Insider Share Purchase by Chairman and ...

BioStem Technologies Announces Insider Share Purchase by Chairman and Chief Executive Officer POMPANO BEACH, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, discloses an insider purchase of common stock from Jason Matuszewski, Chairman and Chief Executive Officer of BioStem Technologies. Mr. Matuszewski purchased a total of 15,500 shares on August 19, 2025, totaling approximately $100,000. The purchases were made through two separat...

 PRESS RELEASE

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial...

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results POMPANO BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today reported preliminary financial results for the second quarter ended June 30, 2025. Recent Business Highlights: Appointed Brandon Poe as Chief Financial Officer, a seasoned financial executive with experience across the healthcare sectorCompleted enrollment in ...

 PRESS RELEASE

BioStem Technologies Appoints Brandon Poe as Chief Financial Officer

BioStem Technologies Appoints Brandon Poe as Chief Financial Officer Seasoned healthcare CFO with senior experience in capital markets and financial operations across private and publicly traded companies to lead BioStem’s financial team POMPANO BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the appointment of Brandon Poe as its Chief Financial Officer (CFO). Mr. Poe has served on BioS...

 PRESS RELEASE

BioStem Technologies to Host Second Quarter 2025 Financial Results Con...

BioStem Technologies to Host Second Quarter 2025 Financial Results Conference Call on August 14, 2025 Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived products for advanced wound care, announces it will release its second quarter 2025 financial results on Thursday, August 14, 2025, and host a conference call and webcast at 4:30 PM ET. The webcast will feature a review of second quarter results and an upd...

 PRESS RELEASE

BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicar...

BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes The Company welcomes CMS’ efforts to reform skin substitute payment policy and will continue to engage with CMS and other stakeholders to optimize the proposed changes POMPANO BEACH, Fla., July 17, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, comments on the Centers for Medicare and Medicaid Services (“CMS”) release of the Calendar...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch